ArticleAmerican journal of translational research2025
Expression and clinical significance of BUB1 in esophageal cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression levels, biological functions, and clinical significance of budding uninhibited by benzimidazoles 1 (BUB1) in esophageal squamous cell carcinoma (ESCC).
methodsA total of 50 pairs of ESCC and adjacent normal tissues were collected for analysis. The human normal esophageal epithelial cell line (Het-1A) and the human esophageal cancer cell line (EC109) were cultured. Cells were transfected with pcDNA 3.1+BUB1 and shRNA-BUB1. The effects of BUB1 on cancer cells were assessed using CCK-8, Transwell migration and invasion assays, real-time quantitative PCR, and Western blot. Immunohistochemical staining was performed to analyze BUB1 expression in cancer tissues. Logistic regression analysis was used to evaluate the association between BUB1 expression and clinicopathological parameters. The predictive value of BUB1 expression for tumor differentiation, lymph node metastasis, and clinical stage was assessed using receiver operating characteristic (ROC) curve analysis.
resultsBUB1 was highly expressed in cancer tissues and cells. Overexpression of BUB1 promoted the proliferation, migration, and invasion of EC109 cells in vitro, while silencing BUB1 inhibited these processes (all P<0.05). The positive expression rate of BUB1 was higher in cancer tissues compared to normal tissues (70% vs. 30%, P<0.05). Logistic regression analysis revealed that BUB1 expression was significantly associated with tumor differentiation, lymph node metastasis, and clinical stage (all P<0.05). ROC curve analysis showed that the area under the curve (AUC) for BUB1 expression predicting tumor differentiation, lymph node metastasis, and clinical stage was 0.762, 0.789, and 0.831, respectively.
conclusionBUB1 promotes the proliferation, migration, and invasion of esophageal cancer cells. Increased BUB1 expression is closely associated with tumor differentiation, lymph node metastasis, and clinical stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.